Navigation Links
HUYA Bioscience International Engages In Partnership With Zhuhai Sanzao Science and Technology Industrial Park

SAN DIEGO, June 8, 2012 /PRNewswire/ -- HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovations, today announced a strategic partnership with Zhuhai Sanzao Science and Technology Industrial Park (Sanzao Park). The collaboration agreement will combine both parties' strength in aiding the advancement of China's pharmaceutical discoveries.

HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing preclinical and early clinical stage compounds from the country, utilizing its expertise to advance these compounds for global markets.

Established in 1999, Sanzao Park is an important part of the Zhuhai National Hi-Tech Development Zone. Located in the Golden Bay district of the city of Zhuhai, Sanzao Park has attracted about 70 biopharmaceutical (including medical devices), drug manufacturing and distribution, and medical services companies to the park, including well known Chinese pharmaceutical companies such as United Lab Pharmaceutical and Yibang Biopharmaceutical.

Under the agreement, Sanzao Park and HUYA will collaborate to promote new drug development. HUYA will have the first opportunity to provide assistance in evaluating research and development projects conducted by pharmaceutical enterprises residing in Sanzao Park. HUYA will also be able to globalize select programs from Sanzao Park through HUYA's innovative co-development model and worldwide pharmaceutical partners.

"We are excited to form a partnership with the Zhuhai Sanzao Science and Technology Industrial Park," said Clement Gingras, HUYA's CTO and COO, China. "Together, we will help promote development of China's emerging bio-pharmaceutical industry."

Responsible persons of Sanzao Park commented, "We are committed to building China's best-known brand in the pharmaceutical industry; with HUYA's knowledge and experience in international drug development, Sanzao Science and Technology Industrial Park hopes to advance its best program to the global market."


HUYA is the leader in global pharmaceutical co-development with Chinese partners. With eight offices strategically located in China, the most comprehensive Chinese compound portfolio, and a rapidly growing number of collaboration agreements with premier Chinese research and development organizations, HUYA is uniquely positioned to identify and license novel Chinese compounds. HUYA offers Western pharmaceutical companies efficient access to innovative therapeutic opportunities and helps to reduce deal-making complexity in China. The company has become a champion of guiding China's biomedical innovations to the worldwide marketplace. HUYA has joint headquarter offices in San Diego, CA, USA and Shanghai, China. Additional information about the company is available at

ABOUT Zhuhai Sanzao Science and Technology Industrial Park

Sanzao Park is an important part of the Zhuhai National Hi-Tech Development Zone, with pharmaceuticals, medical devices, and consumer electronics as its key focus industries. Up to date, it has attracted roughly 500 enterprises from 18 different countries, including 8 Fortune 500 companies, to establish presence in Sanzao Park.  There are 41 manufacturing facilities, representing total investment of 3 billion Chinese Yuan.  In 2011, the output from biomedical enterprises reached 8.5 billion Chinese Yuan, accounting for 1/3 of the industrial output from Sanzao Park.  Among other top honors, Sanzao Park was designated as Guangdong Province "Torch Plan" Biopharmaceutical Production Base.  For more information, please visit http//  


Yung-Chih Wang, Ph.D., MBA
Vice President, Corporate Development, China
HUYA Bioscience International


SOURCE HUYA Bioscience International
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
9. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
10. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
11. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... that immunotherapy can be efficiently combined with photodynamic therapy ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Japanese ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... "Advanced Wound Care Market by Type (Dressings, Therapy Devices, ... (In-Patient Facility, Out-Patient Facility), and Geography - Global Forecast ... --> --> The purpose ... and forecast of the global advanced wound care market. ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... ... Inc., developer and distributor of the world-class Asterisk based contact center software Q-Suite, announces ... new Q-Suite 6 platform is based on the latest Java Enterprise standards. By conforming ... of software for many key components of the suite. Much of the suite runs ...
(Date:11/25/2015)... ... ... Finnleo, a leader in the traditional and far-infrared sauna industry, announced a ... , For traditional saunas, Finnleo is offering 20% off all Nordic ... uses only European Grade A Nordic White Spruce from sustainably grown trees. Because of ...
(Date:11/25/2015)... ... , ... Ministers, senior government and UN agencies, representatives from ... Excellence, and public R&D institutions, civil societies and other partners gathered today at ... Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day meeting ...
(Date:11/25/2015)... Jacksonville, FL (PRWEB) , ... November 25, 2015 ... ... treatment center, is encouraging people across the country to celebrate their sobriety and ... invites people to post “before and after” photos this Thanksgiving with the hashtag ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm ... appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto ... Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified ...
Breaking Medicine News(10 mins):